Please assess the completion status of the following clinical trial:

Trial Title: Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male and female participants with newly diagnosed chronic hepatitis C~* age 18-65~* HCV-RNA positive in serum as measured by PCR~* Genotype 1~* ALT levels according to European labeling~* in women of child-bearing age, pregnancy must be excluded prior to entry into the study, and the use of a safe contraceptive device must be documented; sexually active male participants must practice a method of contraception considered acceptable (vasectomy, condom plus spermicide, plus relationship with a female partner who practices an acceptable method of contraception)~* Lab parameters:~  * Hb: \>=12 g/dL (women) or \>= 13 g/dL (men)~ * leukocytes \>= 3,000/µL~ * thrombocytes \>= 100,000/µL~ * PT/PTT/coagulation must be within normal limits or clinically acceptable to the investigator/sponsor~ * Albumin must be within normal limits or clinically acceptable to the investigator/sponsor~ * creatinine must be within normal limits or clinically acceptable to the investigator/sponsor~ * uric acid must be within normal limits or clinically acceptable to the investigator/sponsor~* antinuclear antibodies \<= 1:160~* signed informed consent~Exclusion Criteria:~* refusal by women of child-bearing age or by sexually active participants to use a safe contraceptive~* breast-feeding women~* cirrhosis stage B and C according to Child-Pugh~* signs of decompensated liver disease~* confirmed co-infection with HIV or HBV~* existing psychiatric comorbidity~* alcohol abuse~* active malignant disease or suspicion or history of malignant disease within 5 previous years (except for adequately treated basal cell carcinoma)~* existing psoriasis or other dermatological disorder~* treatment with a study drug within the last 30 days~* any uncontrolled underlying medical conditions~* clinically significant ECG abnormalities and/or significant cardiovascular dysfunction within the last 6 months. In case of other suspected heart disease, a cardiological examination is required.~* any liver disorder of other genesis than the study indication (with regard to elevated iron levels, only participants with manifest hemochromatosis are excluded)~* autoimmune disorder (except LKM-positive participants).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interventional Study arm (with insulin resistance) (Type: EXPERIMENTAL): HOMA IR (homeostasis model assessment-estimated insulin resistance) of \> 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment.
- Non interventional study arm (without insulin resistance) (Type: EXPERIMENTAL): HOMA IR \<= 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to~European labeling).

Based on this trial design, predict the completion outcome and termination type (if applicable).